Linked Life Data

16919009

Source:http://linkedlifedata.com/resource/pubmed/id/16919009

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2006-8-21
pubmed:abstractText
Bosentan, a dual endothelin receptor antagonist, has been used for symptomatic improvement of patients with idiopathic pulmonary arterial hypertension (PAH) and specific types of secondary (e.g. scleroderma and human immunodeficiency virus infection) PAH, but its efficacy in patients with congenital heart disease and chronic thromboembolic pulmonary hypertension is still under evaluation. In this study two patients are presented, one with common atrioventricular canal and pulmonary hypertension and the other with recurrent pulmonary thromboembolism; both improved significantly after bosentan administration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0014-2972
pubmed:author
pubmed:issnType
Print
pubmed:volume
36 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
39-43
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Bosentan in Eisenmenger syndrome and chronic thromboembolic pulmonary hypertension.
pubmed:affiliation
2nd Department of Cardiology, Hellenic Red Cross General Hospital, Athens, Greece.
pubmed:publicationType
Journal Article, Case Reports